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Suitable reference genes for relative quantification of miRNA
expression in prostate cancer
Abstract
Real time quantitative PCR (qPCR) is the method of choice for miRNA expression studies. For relative
quantification of miRNAs, normalization to proper reference genes is mandatory. Currently, no
validated reference genes for miRNA qPCR in prostate cancer are available. In this study, the
expression of four putative reference genes (hsa-miR-16, hsa-miR-130b, RNU6-2, SNORD7) was
examined with regard to their use as normalizer. After SNORD7 was already shown an inappropriate
reference gene in preliminary experiments using total RNA pools, we studied the expression of the
putative reference genes in tissue and normal adjacent tissue sample pairs from 76 men with untreated
prostate carcinoma collected after radical prostatectomy. hsa-miR-130b and RNU6-2 showed no
significantly different expression between the matched malignant and non-malignant tissue samples,
whereas hsa-miR-16 was significantly underexpressed in malignant tissue. Softwares geNorm and
Normfinder predicted hsa- miR-130b and the geometric mean of hsa-miR-130b and RNU6-2 as the most
stable reference genes. Normalization of the four miRNAs hsa-miR-96, hsa- miR-125b, hsa-miR-205,
and hsa-miR-375, which were previously shown to be regulated, shows that normalization to hsa-mir-16
can lead to biased results. We recommend using hsa-miR-130b or the geometric mean of hsa-miR-130b
and small RNA RNU6-2 for normalization in miRNA expression studies of prostate cancer.
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Abstract
Real time quantitative PCR (qPCR) is the method of 
choice for miRNA expression studies. For relative 
quantification of miRNAs, normalization to proper ref-
erence genes is mandatory. Currently, no validated ref-
erence genes for miRNA qPCR in prostate cancer are 
available. In this study, the expression of four putative 
reference genes (hsa-miR-16, hsa-miR-130b, RNU6-2, 
SNORD7) was examined with regard to their use as 
normalizer. After SNORD7 was already shown an in-
appropriate reference gene in preliminary experiments 
using total RNA pools, we studied the expression of the 
putative reference genes in tissue and normal adjacent 
tissue sample pairs from 76 men with untreated pros-
tate carcinoma collected after radical prostatectomy. 
hsa-miR-130b and RNU6-2 showed no significantly dif-
ferent expression between the matched malignant and 
non-malignant tissue samples, whereas hsa-miR-16 
was significantly underexpressed in malignant tissue. 
Softwares geNorm and Normfinder predicted hsa- 
miR-130b and the geometric mean of hsa-miR-130b 
and RNU6-2 as the most stable reference genes. 
Normalization of the four miRNAs hsa-miR-96, hsa- 
miR-125b, hsa-miR-205, and hsa-miR-375, which were 
previously shown to be regulated, shows that normal-
ization to hsa-mir-16 can lead to biased results. We rec-
ommend using hsa-miR-130b or the geometric mean 
of hsa-miR-130b and small RNA RNU6-2 for normal-
ization in miRNA expression studies of prostate 
cancer.
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Introduction
MicroRNAs (miRNAs) are small non-coding RNAs 
with a length of approximately 22 nucleotides. 
They regulate gene expression by mRNA cleavage 
and at posttranscriptional level by translational 
suppression and play important roles in various 
biological and metabolic processes (Min and Yoon, 
2010). Recent studies have demonstrated their 
decisive significance in tumor development and 
metastasis (Garzon et al., 2009). Bioinformatic pre-
dictions indicate that miRNAs regulate ∼30% of all 
protein coding genes (Filipowicz et al., 2005). It is 
estimated that approximately 1,000 miRNAs exist 
in the vertebrate genome (Berezikov et al., 2005). 
So far, 940 human miRNAs are registered at 
miRBase release 15.0 (http://microrna.sanger.ac. 
uk/; access: July 6, 2010).
    The differential expression of miRNAs depends 
on tissue type and disease status suggesting their 
potential not only as new diagnostic, prognostic, 
and predictive markers, but also as targets of novel 
therapeutic strategies (Lee and Dutta, 2009). 
Therefore, there is a growing interest in miRNA 
profiling in order to identify specific miRNAs with 
diagnostic/therapeutic value, and a wealth of 
miRNA studies can be expected for the near 
future, which will be performed similarly as we 
have seen in the numerous mRNA expression 
studies of the last decade. The methods used to 
study miRNA expression are Northern Blotting, 
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bead-based flow cytometry, microarray technology, 
and quantitative real-time reverse transcription- 
polymerase chain reaction (RT-qPCR) (Bartels and 
Tsongalis, 2009). This latter technique is the 
method of choice for analysis of mRNA expression 
in biological material (Nolan et al., 2006) and new 
techniques have also offered the possibility of 
measuring expression of miRNAs by this technique 
in recent years (Chen et al., 2005). QPCR com-
bines the advantages of high sensitivity and 
specificity and can be used in high-throughput 
approaches. To study changes in a gene of interest 
the relative quantification of expression is the 
generally accepted approach in comparison with 
the absolute quantification working with absolute 
concentrations based on an external or internal 
calibration curve (Bustin et al., 2009). In relative 
quantification, the expression of a target gene is 
normalized to the expression of one or more stably 
expressed endogenous reference genes simul-
taneously measured in the same sample.
    However, several criteria have to be fulfilled to 
render a gene eligible as a reference gene 
(Vandesompele et al., 2002; Bustin and Nolan, 
2004). It should be expressed at a constant 
non-regulated level independent of biological vari-
ations, disease stages or treatments. The stability 
of a given reference gene has to be experimentally 
validated for each study design. The range of 
expression should be similar to that of the target 
gene in order to be able to measure both genes in 
one sample dilution. The reference gene should be 
of similar length as the gene of interest to 
guarantee the same efficiencies during RNA isolat-
ion and reverse transcription.
    In miRNA research, suitable reference genes, 
especially for expression studies in prostate 
cancer, have not been satisfyingly identified. Only 
a few studies have investigated the question of 
reference gene selection in miRNA RT-qPCR. 
Small nucleolar RNAs such as RNU6-2 (RNA, U6 
small nuclear 2; alias RNU6B), SNORD7 (small 
nucleolar RNA C/D box 7; alias Z30), and 
SNORD43 (small nucleoalr RNA C/D box 43; alias 
RNU43) are generally used for normalization of 
miRNA expression studies (Ozen et al., 2008; Leite 
et al., 2009; Spahn et al., 2009; Chang et al., 
2010). Some miRNAs have also been described as 
reference genes for a set of tissues from solid 
tumors (Peltier and Latham, 2008) as well as for 
breast cancer (Davoren et al., 2008). Recently, it 
has been proposed that normalizing to the mean 
expression of all tested miRNAs is superior to 
normalization to one or a pair of stably expressed 
small RNAs (Mestdagh et al., 2009). Yet, this 
approach is limited, as it is only feasible if a large 
number of miRNAs is studied, which is not always 
possible, especially in functional studies.
    We performed a PubMed literature search to 
identify suitable reference genes for miRNA qPCR 
of prostate cancer specimen. We identified 16 
articles (Jiang et al., 2005; Mattie et al., 2006; 
Porkka et al., 2007; Ambs et al., 2008; Josson et 
al., 2008; Mitchell et al., 2008; Ozen et al., 2008; 
Place et al., 2008; Prueitt et al., 2008; Rokhlin et 
al., 2008; Gandellini et al., 2009; Leite et al., 2009; 
Noonan et al., 2009; Siva et al., 2009; Spahn et al., 
2009; Tong et al., 2009), in which miRNA RT-qPCR 
was performed. In 14 articles, relative quantifica-
tion was performed and the reference genes 
utilized were specified. The most commonly used 
reference gene was the small RNA RNU6-2 which 
was used in 4 studies (Jiang et al., 2005; Ambs et 
al., 2008; Prueitt et al., 2008; Noonan et al., 2009). 
Further reference genes or combination of re-
ference genes were: GAPDH (Place et al., 2008; 
Rokhlin et al., 2008) and RNU6-2/SNORD43 
(Ozen et al., 2008; Spahn et al., 2009) (each 
twice), SNORD43 (Leite et al., 2009), TATA box 
binding protein mRNA (Porkka et al., 2007), RNU6- 
2/miR-16 (Josson et al., 2008), RNU6-2/RNaseP 
(Gandellini et al., 2009), and let-7/miR-16 (Mattie 
et al., 2006) (each once). The reasons for selection 
of the reference genes were only given in three 
studies, but these were not satisfying (Jiang et al., 
2005; Mattie et al., 2006; Josson et al., 2008). This 
search clearly showed that an unequivocal recom-
mendation for miRNA reference genes for prostate 
cancer is lacking and a study concerning this issue 
has not been performed until now. On the other 
hand, there has been a lack of agreement regard-
ing differentially expressed miRNAs in prostate 
cancer(Schaefer et al., 2010b). The use of unvali-
dated reference genes seems to be one of the 
major reasons for the discrepancies in miRNA 
expression results between the previously publi-
shed studies (Schaefer et al., 2010b).
    Using the main selection criteria of good mea-
surability and stable expression in non-malignant 
and malignant tissue independent of the stage or 
grade of the tumor, we decided to investigate four 
putative reference genes, two miRNAs (hsa-miR- 
16 and hsa-miR-130b) and two small RNAs 
(RNU6-2 and SNORD7). As mentioned above, 
hsa-miR-16 and RNU6-2 were frequently, but not 
always well-founded in their use as reference 
genes in prostate cancer tissue or prostate cancer 
cell lines (Jiang et al., 2005; Mattie et al., 2006; 
Ambs et al., 2008; Josson et al., 2008; Noonan et 
al., 2009; Ozen et al., 2008; Prueitt et al., 2008; 
Gandellini et al., 2009; Spahn et al., 2009), 
SNORD7 is commercially distributed as reference 
Reference genes for miRNA expression in prostate    751
Figure 1. Expression of reference gene candidates measured in RNA 
pools obtained from matched non-malignant and malignant prostate can-
cer tissue specimens. For each pool, RNA extracts were diluted to the 
same concentration and then equal volumes were mixed to obtain the 
same final concentration in the RNA pools (250 ng/μl) from malignant 
and non-malignant samples, respectively. The first two columns of every 
gene represent the expression values as mean Cq-values± 1 SD (n =
3; blank, non-malignant tissue; grey, malignant tissue) related to the left 
y-axis scale. The third column (black) represents the median fold change 
between pools from non-malignant and malignant tissue related to the 
right y-axis scale. The arbitrary line at 1.5 represents the rough estimate 
of differential expression between non-malignant and malignant tissue, 
as explained in the text.
Reference 
gene approach
pT stage Gleason score
ra P value r P value
Hsa-miR-16 -0.007 0.95 -0.184 0.11
Hsa-miR-130b -0.049 0.67 -0.151 0.19
RNU6-2 -0.050 0.67 0.070 0.51
Geometric mean of -0.067 0.57 -0.022 0.86
 Hsa-miR-130b/RNU6-2
aPearson correlation coefficient.
Table 1. Correlation of the expression of putative reference 
genes with tumor stage and Gleason score.
gene and recommended as generally stable 
reference gene (Pradervand et al., 2009), and we 
recently suggested hsa-miR-130b for normalization 
(Schaefer et al., 2010a). Since it has been pro-
posed that normalization should be done on a set 
of reference genes (Vandesompele et al., 2002), 
we also tested the geometric mean of hsa-miR- 
130b and RNU6-2 as an approach for miRNA 
normalization.
Results
Expression of candidate reference genes
To evaluate the measurability of the putative refer-
ence genes hsa-miR-16, hsa-miR-130b, RNU6-2, 
and SNORD7 and to obtain a rough estimate of 
their expression stability in malignant and non- 
malignant tissue, the expression levels of these 
genes were determined in RNA pools prepared 
from normal and malignant tissue samples. For 
each pool, the same volumes of 12 samples of 
equal RNA concentration were combined as des-
cribed in the Methods section. All reference gene 
candidates were expressed at suitable levels, 
showing good measurability (Figure 1). Hsa-miR- 
16 had the highest expression with mean Cq- 
values below 25. Expression of SNORD7 was the 
lowest, but still with Cq-values below 30, showing 
median fold changes of 1.81 between pools 
(Figure 1; 3rd column). We decided to use a 
change limit of 1.5 as an indicator of differential 
expression. The high arbitrary threshold was 
chosen to minimize risk of type II errors. According 
to that criterion SNORD7 was excluded from 
further analyses. However, RNU6-2 showed a 
mean fold change of 1.48 but was included in the 
subsequent, more detailed search for suitable 
reference genes despite its differential expression 
(Figure 1).
    The expression of the remaining candidate 
genes (hsa-miR-16, hsa-miR-130b, and RNU6-2) 
was then determined in 76 matched pairs of 
malignant and non-malignant tissue specimens 
obtained from non-treated prostate carcinomas 
after radical prostatectomy. For statistical analyses, 
Cq-values were normalized to qPCR efficiency and 
interplate controls using the software GenEx 
(Kubista et al., 2006). Since the expression of 
candidate reference genes did not correlate with 
the Gleason score or tumor stage as the two main 
factors that may determine the expression be-
havior (Table 1), all values were merged, indepen-
dent of the stage and grade of the tumor, into one 
data set for further calculations. There were no 
significant differences between Cq-values in the 
tissue groups for hsa-miR-130b and RNU6-2, 
whereas hsa-miR-16 was significantly underex-
pressed in malignant tissues (Figure 2; P = 0.0002, 
paired t-test). Thus, hsa-miR-16 was excluded on 
this account from further analyses since the high 
number of samples investigated and the high 
significance level allowed both the risk of type I 
and II errors to be excluded with relatively high 
certainty.
    The fact that a reference gene shows no 
statistical difference between groups does not 
mean that its expression is equal in those groups. 
Therefore, we also tested the equivalence of the 
expression values of hsa-miR-130b, RNU6-2 and 
the geometric mean between the malignant and 
non-malignant sample group (Haller et al., 2004). 
The approved difference between the groups was 
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Figure 2. Expression of reference gene candidates in matched non-ma-
lignant and malignant sample pairs from 76 prostate cancer tissue 
specimens. Left y-axis: Expression values are given as Cq-values, which 
were corrected to efficiency and two interplate controls. Boxes (blank:, 
non-malignant tissue; grey: malignant tissue) represent lower and upper 
quartiles with the median as a horizontal line and the mean as a cross. 
The whiskers represent the ranges of expression. Only hsa-miR-16 ex-
pression was significantly different between normal and malignant tissue 
(P = 0.0002, t-test of paired data). Right y-axis: The columns (black) rep-
resent the median fold changes between the malignant and non-malig-
nant tissue samples.
Figure 3. Stability analyses of selected candidate reference genes in the geNorm and 
Normfinder programs. (A) Stability value M of candidate reference genes calculated by 
geNorm. (B) Variability of candidate reference genes calculated by Normfinder. Highly 
stable expression of genes is indicated by a low M value in geNorm and a low varia-
bility value in Normfinder, respectively.
set to 0.26 for all three reference genes, which 
equates to a fold change of 1.2. The expression of 
RNU6-2 in both tissue groups was not equal, when 
using this cut-off, whereas both hsa-miR-130b and 
the geometric mean showed equivalent values in 
the malignant and non-malignant samples.
Stability of candidate reference genes
The overall stability of the expression is a further 
major criterion for a good reference gene. The 
variance of a reference gene over all groups is a 
measure of this stability. We compared the 
variances of hsa-miR-130b and RNU6-2 express-
ion and the geometric mean of both candidates. 
RNU6-2 had a significantly higher variance than 
hsa-miR-130b or the geometric mean (P＜ 0.0001, 
Levene’s test), whereas the variances of hsa- 
miR-130b and the geometric mean did not differ 
significantly (P = 0.52, Levene’s test).
    The stability of candidate reference genes was 
further assessed by the Normfinder and geNorm 
software (Vandesompele et al., 2002; Andersen et 
al., 2004). GeNorm calculates the stability values 
(M-values) for all candidate genes and excludes 
the candidate with the lowest stability and recal-
culates the stability value, until the two most stable 
genes are predicted. In our study, M-values below 
1.5 were defined in the program as the critical limit. 
The geometric mean and hsa-miR-130b were the 
two most stable genes with an M-value of 0.47 
(Figure 3A). Normfinder also calculates a stability 
value, named the variability, for each gene. It 
estimates the single most stable gene and the best 
combination of two genes. In contrast to geNorm it 
can account for group differences. Normfinder 
analysis identified hsa-miR-130b as the single 
most stable gene with a variability of 0.078. The 
geometric mean of hsa-miR-130b and RNU6-2 
lowered the variability to 0.027, substantiating the 
increased stability (Figure 3B).
Effect of normalization on relative quantification of 
miRNA expression of genes of interest
The effect of normalization using either of these 
three reference gene candidates or hsa-miR-16, 
which is itself regulated in prostate cancer, on the 
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Figure 4. Quantitative differences in miRNA expression in prostate can-
cer by normalization with different reference gene approaches. The me-
dian fold changes of hsa-miR-96, hsa-miR-125b, hsa-miR-205, and 
hsa-miR-375 expression in 76 malignant tissue samples in comparison 
to matched normal tissue are presented. Expression was either normal-
ized to hsa-miR-16 (blank columns), RNU6-2 (light grey columns), 
hsa-miR-130b (medium grey columns) or the geometric mean of 
hsa-miR-130b and RNU6-2 (black columns). There were no significant 
differences in any fold changes of expression for the four target miRNAs 
when they were normalized against either RNU6-2, hsa-miR- 130b or the 
geometric mean of hsa-miR-130b and RNU6-2 (Friedman' test with 
Dunn’s post test, P = 0.810). In contrast, the fold changes of all four 
miRNAs normalized against hsa-miR-16 were significantly different from 
the fold changes obtained with the normalization against has-miR- 130b, 
RNU6-2 or the geometric mean of hsa-miR-130b and RNU6-2. Signi-
ficance levels are indicated by letters at the corresponding columns: 
a, P＜ 0.005; b, P ＜ 0.0005 (Wilcoxon test of matched paired sam-
ples).
Figure 5. Effect of the normalization approach on the coefficient of varia-
tion of expression for four miRNAs of interest in prostate cancer. 
Hsa-miR-96, hsa-miR-125b, hsa-miR-205, and hsa-miR-375 were meas-
ured in 76 malignant and matched normal tissues samples. Each group 
was either normalized to hsa-miR-130b, RNU6-2 or the geometric mean 
of both. The coefficient of variation (CV) was calculated for each miRNA 
and tissue group. The box represents the lower and upper quartiles of 
the CV with the median as a horizontal line and the mean as a cross for 
normalization to one of the three reference genes. The whiskers repre-
sent the range of CVs. Significances were calculated by t-test of paired 
data.
expression results for hsa-miR-96, hsa-miR-125b, 
hsa-miR-205, and hsa-miR-375 was tested. These 
four miRNAs of interest were previously shown to 
be differentially regulated in prostate cancer 
(Schaefer et al., 2010a). Comparison of the four 
normalization strategies demonstrated that fold 
changes are indeed significantly influenced by the 
normalization approach (Figure 4). Fold changes 
after normalization to hsa-miR-130b, RNU6-2 or 
their geometric mean did not differ from each other 
(Friedman' test with Dunn’s post test, P = 0.810), 
but the fold changes of all four miRNAs of interest 
normalized with hsa-miR-16 were significantly 
different from those related to the other three 
normalization approaches (Figure 4; Wilcoxon test, 
always P value＜ 0.01).
    As mentioned above, the variation in expression 
of a given gene is composed of biological and 
technical variation and it is the technical variation 
that should be reduced by normalizing with the 
reference genes. Therefore, normalization to a 
more efficient reference gene should result in lower 
coefficients of variation (CV) in the expression data 
of the miRNA of interest. The CVs of the miRNAs 
normalized with RNU6-2 were significantly higher 
than those for the same miRNAs normalized with 
hsa-miR-130b or the geometric mean of hsa-miR- 
130b and RNUB6 (Figure 5; P = 0.0009, Friedman 
test with Dunn´s post test).
Discussion
The relative quantification of gene expression by 
qPCR has become one of the major methods for 
studying miRNA expression in tissues or cell 
cultures, but the worth of this in expression studies 
is strongly dependent on the selection of stably 
expressed reference genes. In this study, we pre-
sent the first experimentally validated comparison 
of reference genes for normalization of miRNA 
expression in prostate cancer. To date, the quest-
ion of which reference genes should be used for 
the relative quantification of miRNA expression 
studies has not been systematically investigated. 
Nevertheless, it is mandatory to validate the ex-
pression of reference genes for each study design, 
as normalization to an unsuitable reference gene 
has been shown to lead to biased results (Dheda 
et al., 2005; Ohl et al., 2005). In the majority of 
miRNA expression studies, miRNAs or other small 
RNAs were used as reference genes, but some 
studies also normalized expression to longer 
mRNAs, namely GAPDH, TATA box binding protein 
mRNA, and RNAseP (Porkka et al., 2007; Huang 
et al., 2008; Place et al., 2008; Rokhlin et al., 2008; 
Gandellini et al., 2009). It is questionable as to 
whether mRNAs can be used as reference genes 
in miRNA expression studies, because longer 
RNAs may have different isolation efficiencies 
compared to miRNAs (Peltier and Latham, 2008), 
they may be degraded faster due to their length, 
and they are reverse transcribed with different 
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techniques than the miRNAs of interest. GAPDH 
has also been shown to be inferior to other 
reference genes (Ohl et al., 2005) and even to be 
regulated in late pathological stages of prostate 
cancer (Rondinelli et al., 1997).
    We investigated the expression of RNU6-2, 
hsa-miR-16, hsa-miR-130b in 76 matched normal 
and malignant prostate cancer tissues. We demon-
strated that hsa-miR-130b is equally and stably 
expressed in normal and malignant prostate tissue 
and has a low expression variance across all 
samples.
    Hsa-miR-16 has previously been used as a 
reference gene (Mattie et al., 2006; Josson et al., 
2008) and has been reported to be similarly 
expressed in PC3 and LNCaP cells (Mattie et al., 
2006). However, hsa-miR-16 expression is signifi-
cantly regulated in prostate cancer tissue in com-
parison to normal tissue as shown in this study and 
also demonstrated by others (Porkka et al., 2007; 
Bonci et al., 2008). This regulation leads to erron-
eous results when other miRNAs are normalized to 
its expression. Due to its under-expression, over- 
expressed miRNAs seem to be much more highly 
expressed, whereas down-regulated miRNAs may 
not seem regulated at all (Figure 4). Therefore, the 
normalization of miRNA expression in prostate 
cancer tissue to hsa-miR-16 is more or less 
inappropriate.
    RNU6-2 is the most common reference gene for 
miRNA expression studies. Two studies of miRNA 
expression in prostate cancer cell lines have 
reported RNU6-2 expression values across the 
studied cell lines and treatment groups (Jiang et 
al., 2005; Josson et al., 2008). Both studies 
showed that RNU6-2 is expressed at comparable 
levels but they did not provide statistical proof of 
their stable expression, they studied expression 
only in prostate cancer cell lines and not in tissue, 
and sample numbers were very low (four and five 
samples, respectively). Here we showed that 
RNU6-2 is not significantly regulated in prostate 
cancer. However, it did not prove to be equally 
expressed when a cut-off of a 1.2-fold allowed 
difference between tissue groups was used. The 
variance in RNU6-2 expression across both tissues 
was significantly higher than that of hsa-miR-130b. 
When hsa-miR-96, hsa-miR-125b, hsa-miR-205, 
and hsa-miR-375 that are some of the miRNAs of 
interest in prostate cancer research (Schaefer et 
al., 2010a) were normalized to RNU6-2 there were 
significantly higher CVs for normalized miRNAs in 
comparison to the CVs when their expression was 
normalized with hsa-miR-130b.
    We also calculated the geometric mean of hsa- 
miR-130b and RNU6-2 expression and used it for 
normalization according to Vandesompele et al. 
(Vandesompele et al., 2002). The geometric mean 
had a significantly lower variance than RNU6-2. 
Accordingly, the normalization of the expression of 
hsa-miR-96, hsa-miR-125b, hsa-miR-205, and 
hsa-miR-375 to the geometric mean also led to 
significantly lower CVs. Although variance and CV 
were significantly higher for RNU6-2 than for the 
geometric mean or hsa-miR-130b, we did not find 
that differences in the selected miRNAs between 
normal and malignant tissue were significantly 
altered when they were normalized to RNU6-2. 
Biased results could occur nevertheless, especially 
when only small samples are examined or when 
regulation of the miRNA of interest is low.
    We also verified our results by analyzing the 
stability of candidate reference genes with geNorm 
or Normfinder. However, the results were limited. It 
is mandatory to use at least three non-regulated 
genes for analysis but five to ten are recom-
mended (Andersen et al., 2004). As we only 
studied two non-regulated small RNAs in our panel 
we included the geometric mean of hsa-miR-130b 
and RNU6-2 in the analyses with geNorm and 
Normfinder, but this is not independent from the 
other genes and therefore may bias the results 
(Vandesompele et al., 2002). Nevertheless, the 
geNorm and Normfinder analyses supported our 
view that normalization to hsa-miR-130b and the 
geometric mean should be preferred to normaliz-
ation to RNU6-2. Another limitation of this study 
was the small number of examined potential 
reference genes. Unfortunately, we were not able 
to investigate more reference genes in this sample 
set due to the limitation of available material. 
However, as the sample number in this study was 
comparably very high (n = 76), we can provide 
strong statistical reliability that the identified refer-
ence genes hsa-miR-130b and RNU6-2 are indeed 
stably expressed. This fact and the use of a 
relatively high arbitrary threshold of differential 
expression in the first round of our approach to 
select reference genes, as explained in the results, 
minimized the risk of type I and II errors of our 
results as far as possible. We believe that this 
result of a stably expressed reference gene pairs 
could be a useful starting point in searching for 
further reference genes.
    The herein investigated reference genes are 
only recommended for miRNA RT-qPCR studies 
as all data are solely based on this platform. We 
checked for miR-130b and RNU6-2 expression in a 
publicly available dataset (GSE23022). While 
RNU6-2 was not available on the chip, miR-130b 
appeared to be slightly upregulated in the 20 
prostate cancers and paired normal adjacent 
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tissues. The discrepancies between both exper-
iments can have several reasons. For example, 
differences in the detection platform, technical and 
experimental errors, and the use of different sam-
ple sets. In conclusion, the observed discrepancies 
underline that suitable reference genes for miRNA 
microarray need to be identified in an independent 
study.
    Further, it is still under consideration, whether 
the use of reference genes is the most suitable 
normalization approach for miRNA microarray 
studies. Other methods are available, which do not 
rely on previously defined reference genes. Pra-
dervand et al. (2009) developed a normalization 
approach based on the assumption that a set of 
miRNAs has the same expression across all 
arrays. These nonchanging miRNAs named in-
variants are identified for each experiment in-
dependently. Beside normalization to reference 
genes and invariants, other normalization strate-
gies exist as quantile normalization or variance 
stabilizing normalization (Meyer et al., 2010), which 
are in part also used for mRNA arrays (Bolstad et 
al., 2003), but adapted to the specific needs for 
miRNA profiling. However, there is no general 
consent, which normalization is superior to the 
others (Pradervand et al., 2009).
    In summary, the careful selection of reference 
genes plays a crucial role in gene expression 
studies. The candidate reference genes have to be 
validated for each study design, as it has been 
proven that even frequently used reference genes 
are not stable under different conditions. We would 
recommend using hsa-miR-130b as single refer-
ence gene or the geometric mean of hsa-miR-130b 
and RNU6-2 as a combined pair for relative 
quantification of miRNA expression studies in 
prostate cancer tissue.
Methods
Patients and tissue samples
Tumor tissue and adjacent normal tissue from 76 men with 
medically untreated prostate carcinoma were collected 
after radical prostatectomy (median age 63 yr, range 49-74 
yr; median pre-operative prostate-specific antigen concen-
tration 6.7 μg/l, range 0.92-41.9 μg/l) and already used in a 
previous study (Schaefer et al., 2010a). Tumor stage was 
determined according to the International Union Against 
Cancer (Sobin and Wittekind, 2002). Forty-five tumors 
were staged as pT2 and 31 as pT3. Tumor grading was 
done according to Gleason (Epstein et al., 2005). Gleason 
score was distributed as follows: one times Gleason score 
5, 31 times Gleason score 6, 30 times Gleason score 7, 
nine times Gleason score 8, and five times Gleason score 
9. Twenty-seven patients had positive surgical margins but 
none had metastases. The decisive selection of samples 
was based on the availability of cryo-preserved tissues.
    The study was approved by the ethical board of the 
hospital. Fresh prostate tissues were sampled directly after 
surgical removal of the gland. One full frontal section, 
which was grossly tumor suspicious, was deep-frozen in 
liquid nitrogen. A diagnostic hematoxylin stain was 
prepared to verify tumor content and to identify areas of 
normal and tumor tissue. These regions of interest were 
punch biopsied, and then another frozen section was 
obtained to ascertain tumor content. Only cases with more 
than 90% tumor tissue were considered for further analysis 
(Schaefer et al., 2010a).
RNA extraction
Frozen matched malignant and non-malignant samples 
were collected in RNAlater Stabilization reagent (Qiagen 
GmbH, Hilden, Germany). RNA was extracted with the 
miRNeasy Mini Kit (Qiagen) and the yield and A260/280 
ratio were monitored with a NanoDropND-100 spectro-
meter (NanoDrop Technologies, Wilmington, DE). The 
mean A260/A280 ratio was 2.00± 0.03. RNA integrity 
numbers were measured with the 2100 Bioanalyzer using 
the RNA 6000 Nano Kit (Agilent Technologies, Santa 
Clara, CA). Only RNA extracts with an RNA integrity 
number ＞6 were included in further analysis. Mean values 
did not differ significantly (P = 0.30, unpaired t-test), with 
mean values of 7.15± 0.62 for normal tissue and 7.26±  
0.73 for malignant tissue. Further analytical details 
corresponded to specifications as reported previously 
(Jung et al., 2009; Schaefer et al., 2010a). 
    To assess the measurability of the expression levels of 
the reference genes, RNA pools were prepared from 12 
RNA extracts obtained from matched paired malignant 
(pT2, n = 7; pT3, n = 5; Gleason score: two times 5 and 6, 
6 times 7, and two times 9) and non-malignant tissue 
specimens. For each pool, RNA extracts were diluted to 
the same concentration (250 ng/μl) and then equal 
volumes (4.5 μl) were mixed to obtain the same final 
concentration in the RNA pools from malignant and 
non-malignant samples, respectively. The RNA concen-
trations of the original solutions and the dilutions as well as 
the final concentrations in the mixtures were monitored and 
verified by NanoDrop spectrophotometry so that both pools 
contained equivalent RNA amounts from every sample.
MiRNA quantitative real-time RT-PCR
For detection of mature miRNAs, a two-step qPCR was 
carried out using the TaqMan MiRNA Assay (Applied 
Biosystems, Foster City, CA) according to the manufac-
turer’s protocol previously described. 6.67 ng total RNA 
were reverse transcribed using miRNA-specific stem- 
looped primers, 10 nmol dNTP mix, 2.6 U RNase Inhibitor, 
33.5 U MultiScribe RT enzyme, and 1× RT Buffer. RT- 
qPCR measurements were performed on the Light Cycler 
480 Instrument (Roche Diagnostics GmbH, Mannheim, 
Germany; Software version 1.3.0) in white 96-well PCR- 
plates with 10 μl final volume including 1 μl RNA-specific 
cDNA, 1× TaqMan Universal PCR Mastermix NoAmpErase 
UNG and gene-specific TaqMan MiRNA Real-Time PCR- 
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Assay solution according to the manufacturer's protocol. 
Samples were measured in triplicate and a no template 
control and two interplate controls were included in each 
PCR run. To minimize the analytical variation, paired 
malignant and non-malignant samples were always 
analyzed on one PCR plate. Analytical precision was 
assessed by intra-run measurements (n = 5) for each 
miRNA and ranged from 0.24 to 0.71% for quantification 
cycle (Cq) values between 24.61 and 30.6.
    GenEX software (MultiD Analyses AB, Göteborg, 
Sweden) was used to analyze and normalize the qPCR 
data (Kubista et al., 2006). Cq-values were corrected to 
PCR efficiencies (E = 0.825) and for differences between 
runs by normalizing with interplate calibrators.
Efficiency:   
  (1)
Interplate normalization:   
 
  

       (2)
    Cq-values of the target miRNAs hsa-miR-96, hsa-miR- 
125b, hsa-miR-205, and hsa-miR-375 were further 
normalized to each selected reference gene and the 
relative concentration was calculated. The relative con-
centration of the miRNA in tumor tissue was further 
normalized to the relative expression of the same miRNA 
in normal tissue to determine the fold changes of 
differential expression in tumor tissue.
Normalization of the gene of interest (GOI) to reference 
gene:
    
 
  

 (3)
Normalization of expression in tumor to expression in 
normal tissue:
     (4)
    Experiments were planned and realized according to the 
MIQE guidelines (Bustin et al., 2009).
Statistical analysis
Statistical analysis of qPCR data was performed with 
GraphPad Prism version 5.03 (GraphPad Software Inc., La 
Jolla, CA). The normality distribution of the data was tested 
by the Kolmogorov-Smirnov test. Parametric (t-test ac-
cording to Student with paired and unpaired values) and 
non-parametric tests (Wilcoxon signed rank test; Mann- 
Whitney U test; Friedman's test with Dunn’s post test) were 
used as appropriate. Significant differences in variance 
were tested by Levene’s F-test. P-values below 0.05 were 
regarded as significant.
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